Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2018, Article ID 3106852, 3 pages
https://doi.org/10.1155/2018/3106852
Case Report

Antiphospholipid Antibody Induced by Nivolumab

Hurley Medical Center, Michigan State University, East Lansing, MI, USA

Correspondence should be addressed to Emad Abu Sitta; moc.cmyelruh@1tisubae

Received 15 August 2017; Revised 5 December 2017; Accepted 12 December 2017; Published 11 January 2018

Academic Editor: Massimo Gentile

Copyright © 2018 Ahmed Aburahma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Brahmer, C. G. Drake, I. Wollner et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167–3175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti–PD-1 antibody in cancer,” New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Topalian, M. Sznol, D. F. McDermott et al., “Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020–1030, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. P. E. Love and S. A. Santoro, “Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance,” Annals of Internal Medicine, vol. 112, no. 9, pp. 682–698, 1990. View at Publisher · View at Google Scholar
  5. J. S. Dlott and R. A. S. Roubey, “Drug-induced lupus anticoagulants and antiphospholipid antibodies,” Current Rheumatology Reports, vol. 14, no. 1, pp. 71–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. T. Merrill, C. Shen, M. Gugnani, R. G. Lahita, and A. B. Mongey, “High prevalence of antiphospholipid antibodies in patients taking procainamide,” Journal of Rheumatology, vol. 24, no. 6, pp. 1083–1088, 1997. View at Google Scholar
  7. J. C. Becker, B. Winkler, S. Klingert, and E. B. Bröcker, “Antiphospholipid syndrome associated with immunotherapy for patients with melanoma,” Cancer, vol. 73, no. 6, pp. 1621–1624, 1994. View at Publisher · View at Google Scholar
  8. J. Delyon, C. Mateus, and T. Lambert, “Hemophilia A induced by ipilimumab,” New England Journal of Medicine, vol. 365, no. 18, pp. 1747-1748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Naldi, F. Locati, G. Finazzi et al., “Antiphospholipid syndrome associated with immunotherapy for patients with melanoma,” Cancer, vol. 75, no. 11, pp. 2784-2785, 1995. View at Publisher · View at Google Scholar
  10. G. Ruiz-Irastorza, M. J. Cuadrado, I. Ruiz-Arruza et al., “Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies,” Lupus, vol. 20, no. 2, pp. 206–218, 2011. View at Publisher · View at Google Scholar · View at Scopus